Literature DB >> 31662094

Validation of the Delirium Diagnostic Tool-Provisional (DDT-Pro) With Medical Inpatients and Comparison With the Confusion Assessment Method Algorithm.

José G Franco1, María V Ocampo1, Juan D Velásquez-Tirado1, Daniel R Zaraza1, Alejandra M Giraldo1, Paola A Serna1, Carolina López1, Adolfo Zuluaga1, Esteban Sepúlveda1, Jacob Kean1, Paula T Trzepacz1.   

Abstract

OBJECTIVE: Delirium remains underdetected as a result of its broad constellation of symptoms and the inadequate neuropsychiatric expertise of most medical-surgical clinicians. Brief, accurate tools are needed to enhance detection.
METHODS: The authors extended validation of the Delirium Diagnostic Tool-Provisional (DDT-Pro), originally validated in a study of inpatients with traumatic brain injury for diagnosis of delirium by nonexpert clinicians, for 200 general medical inpatients in Colombia. The three structured, quantitatively rated items in DDT-Pro represent the three core delirium domains.
RESULTS: High interrater reliability between physician and nurse (0.873) administrators, internal consistency (>0.81), and content validity were found. Compared with independent reference standard diagnosis with DSM-5 or the Delirium Rating Scale-Revised-98, the area under the receiver operating characteristic (ROC) curve (global diagnostic accuracy) range was 93.8%-96.3%. ROC analysis revealed the same cutoff score (≤6) as that for the original study, with somewhat lower sensitivities of 88.0%-90.0% and specificities of 85.3%-81.2% (independent expert physician or nurse ratings). Even when rated by a trained expert physician, the original version of the Confusion Assessment Method algorithm (CAM-A) performed moderately, with lower sensitivities (61.8%-70.0%) than the DDT-Pro (88.0%-100%) and somewhat higher specificities (84.8%-95.3% versus 67.4%-86.7%), with values depending on dementia status, reference standard, and rater type. Accuracies for the DDT-Pro and CAM-A were comparable (DDT-Pro: 83.0%-87.5% versus CAM-A: 87.5%-88.5%), although lower in the dementia subgroup, especially for CAM-A. However, these tools were significantly discordant, especially in negative cases, which suggests that they do not detect diagnosis of patients in the same way.
CONCLUSIONS: The DDT-Pro had high validity and reliability in provisional delirium diagnosis by physicians and nonexpert clinicians, although further validation is warranted before widespread use can be recommended.

Entities:  

Keywords:  Consultation/Liaison Neuropsychiatry; Delirium; Dementia; Nursing Assessment; Psychiatric Status Rating Scales

Mesh:

Year:  2019        PMID: 31662094     DOI: 10.1176/appi.neuropsych.18110255

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  4 in total

1.  Consensus of the Liaison-Psychiatry Committee of the Colombian Psychiatric Association on the Diagnosis and Treatment of Delirium in the Context of the COVID-19 Pandemic.

Authors:  José G Franco; Juan Carlos Molano; Hernán Rincón; Juan David Velasquez Tirado; Carlos Cardeño; Liliana Patarroyo Rodriguez; Gabriel Fernando Oviedo Lugo; Jaime Bernal Miranda; Monica Rojas Moreno
Journal:  Rev Colomb Psiquiatr (Engl Ed)       Date:  2020-12-02

Review 2.  Delirium in Nursing Home Residents: A Narrative Review.

Authors:  Klara Komici; Germano Guerra; Franco Addona; Carlo Fantini
Journal:  Healthcare (Basel)       Date:  2022-08-15

3.  Consensus of the Liaison-Psychiatry Committee of the Colombian Psychiatric Association on the diagnosis and treatment of delirium in the context of the COVID-19 pandemic.

Authors:  José G Franco; Juan Carlos Molano; Hernán Rincón; Juan David Velasquez Tirado; Carlos Cardeño; Liliana Patarroyo Rodriguez; Gabriel Fernando Oviedo Lugo; Jaime Bernal Miranda; Monica Rojas Moreno
Journal:  Rev Colomb Psiquiatr (Engl Ed)       Date:  2022-09-01

4.  Validation of the Korean Version of the Delirium Diagnostic Tool-Provisional (K-DDT-Pro).

Authors:  Kyeong Mee Kim; Man-Shik Shim; Dahyun Yi; So Yeon Jeon; Jeong Lan Kim
Journal:  Psychiatry Investig       Date:  2022-09-22       Impact factor: 3.202

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.